Búsqueda de un ensayo clínico
Otra(s) opcion(es) de búsqueda
107 Resultado(s)
Ensayo clínico en reclutamiento
= 
; Ensayos clínico en curso
= 
; Ensayo clínico finalizado
= 
; Financiado por un miembro del IRDiRC = 
; Miembro de una ERN = 
Ensayo(s) clínico(s) nacional(es)
ALEMANIA
Baden-Württemberg
FREIBURG
A phase III, multicenter, randomized, double-blind, placebo-controlled study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck -DE-
Universitätsklinikum Freiburg
Klinik für Strahlenheilkunde
ALEMANIA
Baden-Württemberg
HEIDELBERG
NOA-20/Improvement of functional outcome for patients with newly diagnosed grade II or III glioma with co-deletion of 1p/19q - IMPROVE CODEL
Neurologische Universitätsklinik Heidelberg
Abteilung für Neuroonkologie
ALEMANIA
Baden-Württemberg
HEIDELBERG
TREASURE: Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease: a Randomized, Open-label, Multicenter Phase II Study - DE
Thoraxklinik-Heidelberg gGmbH
Thoraxklinik Heidelberg
ALEMANIA
Baden-Württemberg
HEIDELBERG
CUPISCO: A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy -DE
Zentrum für Innere Medizin (Krehl-Klinik)
Medizinische Klinik V - Hämatologie, Onkologie und Rheumatologie
ALEMANIA
Baden-Württemberg
MANNHEIM
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - DE
Universitätsmedizin Mannheim
III. Medizinische Klinik
ALEMANIA
Baden-Württemberg
TÜBINGEN
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - DE
Department für Innere Medizin - Medizinische Universitätsklinik Tübingen
Innere Medizin I - Gastroenterologie, Hepatologie und Infektiologie
ALEMANIA
Baden-Württemberg
ULM
CONTACT-03: A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment -DE
Universitätsklinikum Ulm am Michelsberg
Klinik für Kinderurologie
ALEMANIA
Bayern
MÜNCHEN
A phase III, multicenter, randomized, double-blind, placebo-controlled study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck -DE-
Klinikum rechts der Isar der Technischen Universität München
Klinik und Poliklinik für RadioOnkologie und Strahlentherapie
ALEMANIA
Bayern
MÜNCHEN
DEMAND: A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by on-demand selective TACE (sdTACE) upon detection of disease progression or of initial synchronous treatment with TACE and Atezo/Bev on 24-months survival rate in the treatment of unresectable HCC patients
LMU Klinikum der Universität München - Campus Großhadern
Medizinische Klinik und Poliklinik II
ALEMANIA
Bayern
REGENSBURG
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - DE
Universitätsklinikum Regensburg
Klinik und Poliklinik für Strahlentherapie
ALEMANIA
Berlin
ADDRESS: NOT PROVIDED - DE
AGO-OVAR 2.29: Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial - DE
Institution: Information not provided - DE
ALEMANIA
Berlin
ADDRESS: NOT PROVIDED - DE
A phase II, randomized study of MPDL3280A administered as monotherapy or in combination with Bevacizumab versus Sunitinib in patients with untreated advanced renal cell carcinoma - DE
Institution: Information not provided - DE
ALEMANIA
Berlin
ADDRESS: NOT PROVIDED - DE
A Phase Ib/II Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without - DE
Institution: Information not provided - DE
ALEMANIA
Berlin
BERLIN
A phase III, multicenter, randomized, double-blind, placebo-controlled study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck -DE-
Charité - Universitätsmedizin Berlin (CBF)
Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie (CBF)
ALEMANIA
Hamburg
HAMBURG
CONTACT-03: A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment -DE
UKE - Universitätsklinikum Hamburg-Eppendorf
Klinik und Poliklinik für Urologie
ALEMANIA
Hessen
FRANKFURT AM MAIN
CONTACT-03: A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment -DE
Universitätsklinikum Frankfurt
KiRaFe Studienleitung - Klinik für Kinderchirurgie und Kinderurologie
ALEMANIA
Hessen
MARBURG
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - DE
Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg
UKGM - Universitätsklinikum Gießen und Marburg GmbH
ALEMANIA
Niedersachsen
GÖTTINGEN
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - DE
Universitätsmedizin Göttingen
Klinik für Gastroenterologie, gastrointestinale Onkologie und Endokrinologie
ALEMANIA
Nordrhein-Westfalen
BONN
A phase III, multicenter, randomized, double-blind, placebo-controlled study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck -DE-
Universitätsklinikum Bonn (AöR)
Medizinische Klinik und Poliklinik III - Innere Medizin (Onkologie, Hämatologie, Immunonkologie und Rheumatologie)
ALEMANIA
Nordrhein-Westfalen
DÜSSELDORF
ATALANTE : A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab -DE-
Universitätsklinikum Düsseldorf
Frauenklinik
ALEMANIA
Nordrhein-Westfalen
ESSEN
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - DE
Evang. Kliniken Essen-Mitte gGmbH
ALEMANIA
Nordrhein-Westfalen
ESSEN
BOUQUET: A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors -DE
Evang. Kliniken Essen-Mitte gGmbH
Klinik für Gynäkologie & Gynäkologischer Onkologie
ALEMANIA
Nordrhein-Westfalen
ESSEN
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - DE
Universitätsklinikum Essen
Klinik für Strahlentherapie
ALEMANIA
Rheinland-Pfalz
MAINZ
The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage Hepatocellular carcinoma -DE
Universitätsmedizin Mainz
I. Medizinische Klinik und Poliklinik
ALEMANIA
Sachsen
DRESDEN
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - DE
Städtisches Klinikum Dresden
4. Medizinische Klinik - Hämatologie, internistische Onkologie und Palliativmedizin
ALEMANIA
Sachsen
LEIPZIG
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - DE
Universitätsklinikum Leipzig AöR
UCCL - Universitäres Krebszentrum Leipzig
ALEMANIA
Sachsen-Anhalt
MAGDEBURG
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - DE
Universitätsklinikum Magdeburg A.ö.R
Universitätsklinik für Gastroenterologie, Hepatologie und Infektiologie
AUSTRALIA
Victoria
ADDRESS: NOT PROVIDED - AU
A Phase Ib/II Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma -AU
Institution: Information not provided - AU
AUSTRIA
OBERÖSTERREICH
LINZ
IMpower133: A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer - AT
Kepler Universitätsklinikum - Med Campus III.
Klinik für Lungenheilkunde
AUSTRIA
OBERÖSTERREICH
LINZ
IMmotion010: A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy - AT
Ordensklinikum Linz GmbH Elisabethinen
Abteilung für Urologie und Andrologie
AUSTRIA
SALZBURG
SALZBURG
IMagyn050: A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Universitätsklinik für Frauenheilkunde und Geburtshilfe
AUSTRIA
SALZBURG
SALZBURG
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody), in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Universitätsklinik für Innere Medizin III
AUSTRIA
SALZBURG
SALZBURG
IMpower133: A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Universitätsklinik für Pneumologie/Lungenheilkunde
AUSTRIA
SALZBURG
SALZBURG
IMmotion010: A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Universitätsklinik für Urologie und Andrologie
AUSTRIA
STEIERMARK
GRAZ
IMagyn050: A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - AT
KH Barmherzige Brüder Graz - Standort Graz-Marschallgasse
Abteilung für Gynäkologie
AUSTRIA
TIROL
INNSBRUCK
IMagyn050: A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - AT
Medizinische Universität Innsbruck
Universitätsklinik für Gynäkologie und Geburtshilfe
AUSTRIA
TIROL
INNSBRUCK
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody), in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - AT
Medizinische Universität Innsbruck
Universitätsklinik für Innere Medizin V - Hämatologie und Onkologie
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
ATALANTE: A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
AtTEnd: Phase III Double-blind Randomized Placebo Controlled Trial of Atezolizumab in Combination With Paclitaxel and Carboplatin in Women With Advanced/Recurrent Endometrial Cancer - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
An Open-Label, Multicohort, Phase II Study of Atezolizumab in Advanced Solid Tumors (Phase 2) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
PARCT: Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IV Mycosis Fungoides/Sezary Syndrome Patients Relapsed/Refractory After a Previous Systemic Treatment - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
Atezolizumab in combination with Bevacizumab and Chemotherapy versus Bevacizumab and Chemotherapy in recurrent ovarian cancer - a randomized Phase III trial - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
IMbrave251: A Phase III, Open-Label, Randomized Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
TREASURE: Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease: a Randomized, Open-label, Multicenter Phase II Study - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
The ABC-HCC Trial: A Phase IIIb, Randomized, Multicenter, Open-label Trial of Atezolizumab Plus Bevacizumab Versus Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
SPACE: Single-Arm Phase II-Study in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) With Poor Performance Status Receiving Atezolizumab-Carboplatin-Etoposide - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
WIEN
IMmotion010: A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Onkologie
AUSTRIA
WIEN
WIEN
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody), in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Onkologie
AUSTRIA
WIEN
WIEN
IMbrave050: A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Gastroenterologie und Hepatologie
AUSTRIA
WIEN
WIEN
The FAB-HCC Trial: Fecal Microbiota Transplant (FMT) combined with Atezolizumab plus Bevacizumab in Patients with HepatoCellular Carcinoma who failed to respond to prior Immunotherapy - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Gastroenterologie und Hepatologie
AUSTRIA
WIEN
WIEN
IMagyn050: A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - AT
Allgemeines Krankenhaus der Stadt Wien
Universitätsklinik für Frauenheilkunde
AUSTRIA
WIEN
WIEN
IMpower133: A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer - AT
Krankenhaus Nord - Klinik Floridsdorf
Abteilung für Innere Medizin und Pneumologie
AUSTRIA
WIEN
WIEN
IMpower133: A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer - AT
Sozialmedizinisches Zentrum Baumgartner Höhe / Otto Wagner-Spital
2. Interne Lungenabteilung
AUSTRIA
WIEN
WIEN
An early-phase, multicenter, open-label study of the safety and pharmacokinetics of anti-PD-L1 antibody (MPDL3280A) in pediatric and young adult patients with previously treated solid tumors (phase I-II) - AT
St. Anna Kinderspital
Zentrum für Kinder- und Jugendheilkunde
BELGICA
ANTWERPEN
EDEGEM (ANTWERPEN)
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - BE
Antwerp University Hospital - UZA
Department of Medical Oncology
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
ATALANTE : A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab - BE
Institution: Information not provided - BE
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
ANDERLECHT (BRUSSELS)
A Phase Ib/II Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - BE
Institut Jules Bordet Instituut
Service d'hématologie - Institut Jules Bordet
BELGICA
LIEGE
LIEGE
BEAT-meso: A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma - BE
CHU de Liège - Domaine universitaire du Sart Tilman
Pneumologie - Allergologie
BELGICA
VLAAMS BRABANT
LEUVEN
IMbrave251: A Phase III, Open-Label, Randomized Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab - BE
UZ Leuven - Campus Gasthuisberg
Dienst maag-, darm- en leverziekten (gastro-enterologie en hepatologie)
CANADA
Québec
ADDRESS: NOT PROVIDED - CA
A phase III, multicenter, randomized, Double-blind, placebo-controlled study of Atezolizumab (anti pd-l1 antibody) as Adjuvant therapy after definitive local Therapy in patients with high-risk Locally advanced squamous cell Carcinoma of the head and neck-CA
Institution: Information not provided - CA
ESPAÑA
Cataluña
BARCELONA
VENEZO-LUNG: Ensayo de fase Ib/II de la combinación de atezolizumab con vacunación de células dendríticas como tratamiento de mantenimiento en pacientes con cáncer de pulmón de células pequeñas en estadio extendido (CPCP-EE) después del tratamiento de inducción -ES
Hospital Universitari Dexeus - Grupo Quirónsalud
Servicio de Oncología médica
ESPAÑA
Cataluña
ESPLUGUES DE LLOBREGAT
Estudio en fase temprana, multicéntrico, abierto, de la seguridad y farmacocinética del anticuerpo Anti PD-L1 (MPDL3280A) en pacientes pediátricos y adultos jóvenes con tumores sólidos previamente tratados -ES (finalizado)
Hospital Sant Joan de Déu Barcelona
Servicio de Oncología y Hematología
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio fase II, aleatorizado de MPDL3280A administrado como monoterapia o en combinación con bevacizumab frente a sunitinib en pacientes con carcinoma avanzado de células renales no tratado (finalizado)
Institution: Information not provided - ES
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
ATALANTE: Estudio aleatorizado, doble ciego y de fase III de atezolizumab frente a placebo en pacientes con recidiva tardía de cáncer epitelial de ovario, de trompa de Falopio o peritoneal tratado con quimioterapia basada en platino y bevacizumab -ES
Institution: Information not provided - ES
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo de atezolizumab (anticuerpo anti-PD-L1) como terapia adyuvante tras terapia local definitiva, en pacientes con carcinoma de cabeza y cuello de células escamosas con alto riesgo localmente avanzado -ES
Institution: Information not provided - ES
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
PARCT: Ensayo en fase II de atezolizumab (anti-PD-L1) en el tratamiento de pacientes con micosis fungoide/síndrome de Sézary en estadio IIb-IV, recidivante/resistente después de un tratamiento sistémico previo -ES (finalizado)
Institution: Information not provided - ES
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
BEAT-meso: Ensayo clínico Fase III multicéntrico aleatorizado que compara atezolizumab más bevacizumab y la quimioterapia habitual con bevacizumab y la quimioterapia habitual como tratamiento de primera línea para el mesotelioma pleural maligno
Institution: Information not provided - ES
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
SKYSCRAPER-07: Estudio de fase III, aleatorizado, doble ciego y controlado con placebo de atezolizumab con o sin tiragolumab (anticuerpo anti-TIGIT) en pacientes con carcinoma epidermoide de esófago localmente avanzado irresecable -ES
Institution: Information not provided - ES
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
IMbrave251: Estudio de fase III, abierto y aleatorizado de atezolizumab con lenvatinib o sorafenib en comparación con lenvatinib o sorafenib en monoterapia en carcinoma hepatocelular tratado previamente con atezolizumab y bevacizumab
Institution: Information not provided - ES
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
Ensayo ABC-HCC: Ensayo en fase IIIb, aleatorizado, multicéntrico y abierto de atezolizumab más bevacizumab frente a quimioembolización transarterial (QETA) en carcinoma hepatocelular en estadio intermedio -ES
Institution: Information not provided - ES
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
Ensayo multicéntrico, abierto, de fase Ib/II para evaluar la seguridad y la eficacia de la combinación de bosutinib más atezolizumab en pacientes con leucemia mieloide crónica recién diagnosticada
Institution: Information not provided - ES
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio fase II de seguridad y eficacia de Atezolizumab administrado en combinación con terapia anti-CD20 Obinutuzumab o Rituximab en pacientes con linfoma de células del manto o de la zona marginal y macroglobulinemia de Waldenström refractarios o en recaída (finalizado)
Institution: Information not provided - ES
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
IMpower133: Estudio fase I/III, aleatorizado, doble ciego y controlado con placebo de carboplatino más etopósido con o sin atezolizumab (anticuerpo anti-PD-L1) en pacientes con cáncer de pulmón microcítico en etapa avanzada no tratado -ES (finalizado)
Institution: Information not provided - ES
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
IMbrave150: Estudio de fase III, abierto y aleatorizado de atezolizumab en combinación con bevacizumab en comparación con sorafenib en pacientes con carcinoma hepatocelular localmente avanzado o metastásico no tratado -ES (finalizado)
Institution: Information not provided - ES
ESPAÑA
Madrid
MADRID
2SMALL: Estudio de fase I-II para evaluar la seguridad, tolerabilidad y eficacia de PM01183 y atezolizumab en pacientes con cáncer de pulmón de células pequeñas avanzado que hayan progresado tras una quimioterapia previa de platino
Hospital Universitario 12 de Octubre
Servicio de Oncología Médica
FRANCIA
AUVERGNE-RHONE-ALPES
LYON
ATHENA: A European, Multi-centre Phase II Trial of Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck (HNSCC).
CLCC Léon Bérard
Centre Léon Bérard
FRANCIA
BRETAGNE
RENNES
Phase Ib Study Evaluating the Safety and Efficacy of Intratumoral Agonistic Anti-CD40 (Selicrelumab) in Combination With Anti-PDL1 (Atezolizumab) in Patients With Refractory or Relapsed B Cell Lymphoma
CHU de Rennes - Hôpital Pontchaillou
CHU Rennes
FRANCIA
GRAND-EST
STRASBOURG
ATALANTE : A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab - FR
CHU de Strasbourg - Hôpital de Hautepierre
Pôle d'Onco-hématologie
FRANCIA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Phase II Study of the Anti-PDL1 Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid to Investigate Safety and Efficacy of This Combination in Recurrent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal - FR
Institution: Information not provided - FR
FRANCIA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
CONTACT-03: A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment -FR
Institution: Information not provided - FR
FRANCIA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
TRIPLET: Randomised, Open-label, Phase II-III Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy -FR
Institution: Information not provided - FR
FRANCIA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
HOLMBRAVE : Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial 166Holmium Radiation Therapy in Combination With Atezolizumab and Bevacizumab for Non Resectable Hepatocellular Carcinoma
Institution: Information not provided - FR
FRANCIA
HAUTS-DE-FRANCE
LILLE
A phase Ib/II study evaluating the safety and efficacy of Atezolizumab in combination with Obinutuzumab plus Lenalidomide in patients with relapsed or refractory follicular lymphoma - FR
CHRU de Lille - Hôpital Claude Huriez
Service des Maladies du sang
FRANCIA
ILE-DE-FRANCE
PARIS
A Phase II, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) Administered as Monotherapy or in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma - FR
AP-HP. Centre - Université de Paris - HEGP Hôpital Européen Georges Pompidou
Service d'Oncologie Médicale
FRANCIA
OCCITANIE
MONTPELLIER
GATA : A Phase II Trial Evaluating Combination of Atezolizumab, With Venetoclax and Obinutuzumab for Relapsed/Refractory Lymphomas
CHU de Montpellier - Hôpital Saint-Eloi
Département d'Hématologie clinique
FRANCIA
OCCITANIE
MONTPELLIER
Neoadjuvant Atezolizumab and Adjuvant Atezolizumab + Bevacizumab in Combination With Percutaneous Radiofrequency Ablation of Small HCC: a Multicenter Randomized Phase II Trial
ICM - Institut régional du Cancer de Montpellier
Service d'oncologie médicale - Médecine B3
ITALIA
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A phase Ib/II study evaluating the safety and efficacy of MPDL3280A in combination with either obinutuzumab plus bendamustine or obinutuzumab plus CHOP in patients with follicular lymphoma or diffuse large B-cell lymphoma - IT
Institution: Information not provided - IT
ITALIA
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Phase II, Randomized Study of Atezolizumab Administered as Monotherapy or In Combination With Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma - IT
Institution: Information not provided - IT
ITALIA
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Phase IIIB, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
Institution: Information not provided - IT
JAPON
JAPAN
ADDRESS : NOT PROVIDED - JP
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma - JP
Institution: Information not provided - JP
JAPON
JAPAN
ADDRESS : NOT PROVIDED - JP
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Hepatocellular Carcinoma
Institution: Information not provided - JP
JAPON
JAPAN
ADDRESS : NOT PROVIDED - JP
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab - JP
Institution: Information not provided - JP
JAPON
JAPAN
ADDRESS : NOT PROVIDED - JP
CONTACT-03 A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment - JP
Institution: Information not provided - JP
REINO UNIDO (EL)
Greater London
ADDRESS: NOT PROVIDED - GB
A Phase Ib/II Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma -GB
Institution: Information not provided - GB
REINO UNIDO (EL)
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF ATEZOLIZUMAB IN COMBINATION WITH OBINUTUZUMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA - GB
Institution: Information not provided - UK
REINO UNIDO (EL)
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A Phase II, Randomized Study of Atezolizumab Administered as Monotherapy or In Combination With Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma - GB
Institution: Information not provided - UK
REINO UNIDO (EL)
Hampshire
SOUTHAMPTON
ARGO A phase II study of atezolizumab with rituximab, gemcitabine and oxaliplatin in patients with relapsed or refractory diffuse large b-cell lymphoma who are not candidates for high-dose therapy GB
Southampton General Hospital
Southampton University Hospitals NHS Trust Headquarters
REINO UNIDO (EL)
South Glamorgan
CARDIFF
A phase III, multicenter, randomized, Double-blind, placebo-controlled study of Atezolizumab (anti pd-l1 antibody) as Adjuvant therapy after definitive local Therapy in patients with high-risk Locally advanced squamous cell Carcinoma of the head and neck-GB
Velindre hospital
Velindre NHS Trust
SUIZA
Suisse Alémanique
BASEL
A phase III, multicenter, randomized, Double-blind, placebo-controlled study of Atezolizumab (anti pd-l1 antibody) as Adjuvant therapy after definitive local Therapy in patients with high-risk Locally advanced squamous cell Carcinoma of the head and neck-GB
Hoffmann-La Roche
Hoffmann - La Roche Ltd.
SUIZA
Suisse Alémanique
BERN
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - CH
Universitätsspital Inselspital
University Hospital Inselspital
SUIZA
Suisse Alémanique
LUZERN
MOLTO: A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination With Atezolizumab and Obinutuzumab in Richter Transformation of CLL - CH
Luzerner Kantonsspital
Abteilung für Hämatologie
SUIZA
Suisse Alémanique
ZÜRICH
SAKK 17/18 : Overcoming Resistance to Immunotherapy Combining Gemcitabine With Atezolizumab in Advanced NSCLC and Mesothelioma Progressing Under Immune-checkpoint Inhibitors or Gemcitabine. A Multicenter, Single-arm, Open Label Phase II Trial With Two Cohorts
Universitätsspital Zürich
Klinik für Medizinische Onkologie und Hämatologie
SUIZA
Suisse Alémanique
ZÜRICH
MOLTO: A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination With Atezolizumab and Obinutuzumab in Richter Transformation of CLL - CH
Universitätsspital Zürich
Klinik für Medizinische Onkologie und Hämatologie
SUIZA
Suisse Alémanique
ZÜRICH
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - CH
Universitätsspital Zürich
Klinik für Onkologie
SUIZA
Suisse Italienne
BELLINZONA
MOLTO: A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination With Atezolizumab and Obinutuzumab in Richter Transformation of CLL - CH
Istituto di Ricerca in Biomedicina
Istituto oncologico di ricerca (IOR)
SUIZA
Suisse Romande
ADDRESS: NOT PROVIDED - CH